Anil Kapur

CIK: 0001730703

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

VSTM

Verastem, Inc.

Director

NRIX

Nurix Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VSTM
Verastem, Inc.
May 21, 2026
Award(A)
Direct
36K shares-
NRIX
Nurix Therapeutics, Inc.
May 15, 2026
Award(A)
Director Stock Option (right to buy)
Direct
31.3K shares-
VSTM
Verastem, Inc.
May 22, 2025
Award(A)
Direct
8.3K shares-
NRIX
Nurix Therapeutics, Inc.
May 19, 2025
Award(A)
Director Stock Option (right to buy)
Direct
25K shares-
NRIX
Nurix Therapeutics, Inc.
Oct 15, 2024
Award(A)
Director Stock Option (right to buy)
Direct
50K shares-

		Type	Shares	Price		Ownership
May 21, 2026	VSTM Verastem, Inc.	Award(A)	36,000	-	$0	Direct
May 15, 2026	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	31,250	-	-	Direct
May 22, 2025	VSTM Verastem, Inc.	Award(A)	8,333	-	-	Direct
May 19, 2025	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	25,000	-	-	Direct
Oct 15, 2024	NRIX Nurix Therapeutics, Inc.	Award(A) Director Stock Option (right to buy)	50,000	-	-	Direct

1-5 of 5 transactions

About Kapur Anil

Kapur Anil (SEC CIK 0001730703) files insider reports with the SEC as Director of Verastem, Inc. (VSTM) and Director of Nurix Therapeutics, Inc. (NRIX).

Signal8 holds 6 ownership filings by Kapur Anil (1 Form 3, 5 Form 4), filed between Oct 16, 2024 and May 26, 2026. Those filings report 5 transactions, from Oct 15, 2024 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Kapur Anil's filings is in SAN FRANCISCO, CA.

Recent filings by Kapur Anil

May 21, 2026: Grant or award of VSTM shares (Form 4, code A).
May 15, 2026: Grant or award of NRIX derivative securities (Form 4, code A).
May 22, 2025: Grant or award of VSTM shares (Form 4, code A).
May 19, 2025: Grant or award of NRIX derivative securities (Form 4, code A).
Oct 15, 2024: Grant or award of NRIX derivative securities (Form 4, code A).

Other insiders filing for Verastem, Inc. (VSTM)

Paterson Dan, President and CEO
Calkins Daniel, Chief Financial Officer
BAILEY MICHAEL P, Director
Tollefson Karin Anna, Director
Stuglik Brian M, Director
Rowinsky Eric K, Director

How to read Form 4 transaction codes